Researchers at City of Hope Cancer Center are exploring the role of the gut microbiome in cancer treatment, highlighting its potential to improve patient outcomes. This comes in the wake of significant advancements in the understanding of how gut bacteria interact with the immune system in patients undergoing treatments like immunotherapy, reports BritPanorama.
At the forefront of this research is Dr. Marcel van den Brink, who has shifted the focus of cancer treatment towards understanding how gut microbes influence treatment responses. Historically, patients receiving allogenic hematopoietic cell transplants underwent extensive immunosuppressive therapies, which often led to severe, life-threatening infections due to the destruction of their immune systems. In the 1990s, it was noted that about a quarter of these patients succumbed to infections despite rigorous protocols.
Recent findings indicate that antibiotics, while crucial in managing infections, can inadvertently disrupt the balance of gut microbiota, leading to complications such as graft-versus-host disease, where transplanted immune cells start attacking the host’s tissues. The recognition that previous treatment methods contributed to adverse outcomes has prompted a fresh perspective on patient management.
This evolving viewpoint was underscored at a recent symposium attended by US Health and Human Services Secretary Robert F. Kennedy Jr., where experts referred to the microbiome as “the next frontier of cancer prevention and care.” The American Society of Clinical Oncology has identified nearly 100 studies exploring ways to manipulate the gut microbiome to enhance cancer treatments.
The emerging research aligns with the ongoing clinical trial at University Hospitals Seidman Cancer Center in Cleveland, where a kidney cancer patient is set to become the first participant in a late-phase trial using probiotics to enhance immunotherapy outcomes. This study will test the strain of bacteria known as Clostridium butyricum, already a popular dietary supplement in Japan.
Other research at City of Hope has illustrated compelling connections between dietary habits and treatment efficacy. A 2021 study from the University of Texas MD Anderson Cancer Center indicated that a high-fiber diet substantially improved treatment responses among melanoma patients. The challenge for clinicians lies in maintaining a healthy gut environment amidst the various treatment protocols that often involve antibiotics.
Dr. Sumanta Pal at City of Hope, who has been deeply involved in the research, traces the drive towards investigating the microbiome back to discussions on animal health in the poultry industry. Enhanced health in livestock, attributed to the manipulation of gut bacteria through dietary supplements, has parallels in cancer patients’ treatment strategies.
A significant aspect of the current research involves reducing the use of broad-spectrum antibiotics, which, as noted by Dr. Arielle Elkrief, has sharply decreased in lung cancer patients. This cautious approach aims to preserve the beneficial bacteria that support immune function.
Studies conducted on fecal transplants have further illustrated the potential benefits of restoring beneficial bacteria to improve patient outcomes. Early results suggest that combining immunotherapy with fecal transplants from healthy donors can significantly enhance treatment responses in cancer patients, as demonstrated in recent trials published in notable medical journals.
As the scientific community delves deeper into the intricacies of the microbiome and its interactions with treatment protocols, City of Hope’s initiatives—including improved nutritional programs and ongoing research—represent a concerted effort to refine cancer care. Researchers aim to transform dietary approaches into integral components of treatment regimens, reflective of a broader understanding of the body’s complexities in managing health and disease.
Dr. van den Brink’s assertion that “we’re looking to make diet into a drug” encapsulates the ongoing journey towards comprehending the delicate balance of the microbiome in relation to cancer treatment, an area that promises continued exploration and innovation.
